Bortezomib (PS-341)

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Product Use Citation(141)

Customer Product Validation(19)

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
MCF-7MkP3R5l1d3SxeHnjJGF{e2G7NUDke2h7PTBizszNMkD0OFghcA>?NXXWNZh1TE2VTx?=MYDLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml
OVCA 429NFnCNY5HfW6ldHnvckBCe3OjeR?=MVGzNFAhdk1?NGi4Z3I1QCCqNW\uSI5tTE2VTx?=NGr3[3BFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>
RPMI8226MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPKNVAxKG6PNGnhRXc1QCCqNGrRbXpFVVORM13Md2lEPTB;M{Cgcm0>
Dox40MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rpPVExOCCwTR?=MmPSOFghcA>?M1voZ2ROW09?MWjJR|UxRTRyIH7N
MR20MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS0NVAxKG6PMoLHOFghcA>?NGXicG9FVVORM2XYb2lEPTB;MkCgcm0>
LR5NFvaXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\hRmY4OTByIH7NMVS0PEBpMnnESG1UVw>?NV\UXZZvUUN3ME2yNEBvVQ>?
U266NUDWemlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVGxNFAhdk1?MmjIOFghcA>?MV;EUXNQM1TMdGlEPTB;MzDuUS=>
IM-9NWLFXJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHVOogyODBibl2=M2rTSVQ5KGh?MUTEUXNQNHrXdY5KSzVyPU[gcm0>
Hs SultanM3:5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi1Z3MyODBibl2=NVe1Z45mPDhiaB?=NUjpeVBuTE2VTx?=M1LKTWlEPTB;MkCgcm0>
PAM-LY2MXjGeY5kfGmxbjDBd5NigQ>?NXXhSpNHOTByIH7NMofNNVIhcA>?MonZSG1UVw>?M1jQVGlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u
PAM 212MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPnNVAxKG6PMWK3NkBpMUXEUXNQM4LTW2lvcGmkaYTzJINmdGxidnnhZoltcXS7
PAM-LY2NHzaRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\MNVAxKG6PM4Hmc|czKGh?MWLEUXNQNIj5eWtKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=
B4B8NYDsU4xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPERnFEOTByIH7NMWC3NkBpM{TTN2ROW09?NGXEc4ZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=
B7E3M2\zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYOxNFAhdk1?MUK3NkBpM{T5dmROW09?MUDJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?
UM-SCC-9M2XjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{[4V|ExOCCwTR?=MYK3NkBpMULEUXNQMXXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?
UM-SCC-11BNUXJc|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLVWFdEOTByIH7NM2rzTFczKGh?M1PJdWROW09?M2XldGlvcGmkaYTzJINmdGxidnnhZoltcXS7
H460NVWzTo91TnWwY4Tpc44hSXO|YYm=M1TCW|ExKM7:TR?=M{TvNVI1KGh?MWfEUXNQNHvkV4VKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2
U266MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorHOVAxKG6pL33sMYS0PEBpMX;EUXNQMUHJcohq[mm2czDj[YxtKGe{b4f0bC=>
ARH77M3viSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWi1NFAhdmdxbXy=MXu0PEBpMnrJSG1UVw>?Mle3TY5pcWKrdIOgZ4VtdCCpcn;3eIg>
WAD-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWSwRoRZPTByIH7nM41tNYTwU49MPDhiaB?=MYrEUXNQMl;hTY5pcWKrdIOgZ4VtdCCpcn;3eIg>
U266/LR7M4f0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH33dms2ODBibnevcYw>M3O3[FQ5KGh?MXLEUXNQM13EVGlvcGmkaYTzJINmdGxiZ4Lve5Rp
U266/dox4MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYr1fYQ5PTByIH7nM41tM33GOVQ5KGh?NYXN[ZFVTE2VTx?=MnTzTY5pcWKrdIOgZ4VtdCCpcn;3eIg>
RPMI8226/LR5M1TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\QOVAxKG6pL33sMljqOFghcA>?MmPiSG1UVw>?MlrjTY5pcWKrdIOgZ4VtdCCpcn;3eIg>
H460NFrCWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIO4S|YyOCEQvF2=NFfTXYU4OiCqMYrEUXNQMX7JR|UxRTFyMDDuUS=>
H358Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIr1bXYyOCEQvF2=MXi3NkBpMkXPSG1UVw>?NHX3e2pKSzVyPUewJI5O
H322NUTabnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7aNVAh|ryPM1P2XFczKGh?Mnj0SG1UVw>?NXmyWXdZUUN3ME22NlAhdk1?
H460M3nmOmZ2dmO2aX;uJGF{e2G7MX6xNFAhdk1?M1PqTVI1KGh?MXHEUXNQMmXlTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>?
LNCap-Pro5NWX6XlVoTnWwY4Tpc44hSXO|YYm=M4fmXVEh|ryPNGL5cXU1KGh?NFf5XXZFVVORNVn6ZmtTW3SjYnnsbZpmeyCyNUO=
T29MkPTRZBweHSxc3nzJGF{e2G7NVuwS5VwPTBibl2=M3\2dFQ5KGhiMYXEUXNQM1yxfGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?
T29Kt1M2niTGFxd3C2b4Ppd{BCe3OjeR?=M{n2d|UxKG6PM1\UVFQ5KGhiNHS5[WdFVVORNUTYcVlKUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=
HCT116NXnVdVV3SXCxcITvd4l{KEG|c3H5MkLHOVAhdk1?MnqyOFghcCB?NWrlfJhITE2VTx?=NUPicJM2UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=
HKe-3M370XGFxd3C2b4Ppd{BCe3OjeR?=NHi1c|k2OCCwTR?=Mn\wOFghcCB?MWrEUXNQMkPyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?
NB-1691MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjmW5AyKM7:TR?=MYi3NkBpMmPiTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn
CHLA-255MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17pO|Eh|ryPMXG3NkBpMXnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV?
SK-N-ASM1HDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\yWWdPOSEQvF2=NF;3fm44OiCqM3jPWmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW=
NB-1691NXTvfoNHTnWwY4Tpc44hSXO|YYm=MUmxNEBvVQ>?NFnUNnQzPCCqNXWyUIw3W2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>?
CHLA-255MVrGeY5kfGmxbjDBd5NigQ>?MnHCNVAhdk1?M3[5bVI1KGh?NU\BV3g6VW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W=
RPMI 8226M3Tq[GZ2dmO2aX;uJGF{e2G7MlHGNlAhdk1?M2PIblghcA>?M2nzXXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6
MM.1SNUPLR2xNTnWwY4Tpc44hSXO|YYm=MlrNNlAhdk1?MnfqPEBpNUPD[FJOW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?
U266M33ldmZ2dmO2aX;uJGF{e2G7MmnTNlAhdk1?MnXzPEBpMV7TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>
OPM1NW\vTWlYTnWwY4Tpc44hSXO|YYm=NI\m[lAzOCCwTR?=MkC2PEBpMVfTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>
INA6NH3jZmpHfW6ldHnvckBCe3OjeR?=NGL3OVUzOCCwTR?=Mn;oPEBpM2D1dnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6
OPM2MlfFSpVv[3Srb36gRZN{[Xl?NVjuR5JLOjBibl2=NEOw[IY5KGh?MmDTV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>
RPMI 8226NEjyeHJHfW6ldHnvckBCe3OjeR?=MVKyNEBvVQ>?NHPkSHU5KGh?M3zKWGlv\HWlZYOgSG5CKHO7boTo[ZNqew>?
BaF/3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEW2SHYyODBibl2=MYK0PEBpNGjifXNKSzVyPU[uNkBvVQ>?
BaF/3-p210M{nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XSZVExOCCwTR?=NFXmXYo1QCCqMWDJR|UxRTRwNzDuUS=>
TCC-SMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jQfVExOCCwTR?=MoGzOFghcA>?MoDmTWM2OD1{Lkigcm0>
BaF/3NUnFPHJlTnWwY4Tpc44hSXO|YYm=Ml;nOkBvVQ>?NEXmNGI1QCCqM4fvNWlv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>
BaF/3-p210NYS4TY1tTnWwY4Tpc44hSXO|YYm=MnThOkBvVQ>?MmXoOFghcA>?NVj3OnE6UW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>?
BaF/3-p210MlXISpVv[3Srb36gRZN{[Xl?M{XmWFYhdk1?MUCyOEBpM3r3dHJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk
RajiMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULkWZdkOSEQvF2=M3TaWFI1KGh?NWLPb5hmWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg
LCL-1NGLNd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\xNUDPxE1?NHPSV2czPCCqM4O2VnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=
LCL-2NITjeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TTeVEh|ryPNXHiUJdYOjRiaB?=NH\4bpZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=
BJABNIjoXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG2ZZBXOSEQvF2=MXKyOEBpM3TjUHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=
SNT-13NWj6UnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXqxJO69VQ>?MXuyOEBpMXHS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?
SNT-16NGLKWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoiyNUDPxE1?NYDUfJB4OjRiaB?=M1zZVnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=
JurkatMkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\QSVEh|ryPNIDsR3kzPCCqNF7hfFBT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=
KAI-3NITpcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXexRYxWOSEQvF2=MlPYNlQhcA>?MnjlVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi
SNK-6NU\EPIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnzUGgyKM7:TR?=M3;VR|I1KGh?M3zX[3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=
KHYG-1NFjEd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17ZRVEh|ryPNHL5VWszPCCqM1HobHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=
SNT-16NEOxc|ZCeG:ydH;zbZMhSXO|YYm=M123clEh|ryPMm\XOkBpMV;JcoR2[2W|IHPlcIwh[XCxcITvd4l{
JurkatNULiXWZGSXCxcITvd4l{KEG|c3H5NVTJdmVZOSEQvF2=MojDOkBpMUHJcoR2[2W|IHPlcIwh[XCxcITvd4l{
KAI-3NVHGZVBJSXCxcITvd4l{KEG|c3H5NULKOHBSOSEQvF2=MWi2JIg>M3LqTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?
KHYG-1M{\meWFxd3C2b4Ppd{BCe3OjeR?=NUTTW|RmOSEQvF2=MXu2JIg>NVi1OnhlUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=
SNT-13M1iwcWFvfGm4aYLhcEBCe3OjeR?=MkHXNUDPxE1?NIHVXlUzPCCqNYDxeGdYUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY
SNT-16M1XaemFvfGm4aYLhcEBCe3OjeR?=MlfZNUDPxE1?MVuyOEBpNYrSd2dsUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY
KAI-3NGPEZo5CdnSrdnnyZYwhSXO|YYm=Mn3DNUDPxE1?M1yyR|I1KGh?MkPZTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX
SNK-6NWX3do5ESW62aY\pdoFtKEG|c3H5NF71eIQyKM7:TR?=M2jQZVI1KGh?M1TMXWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?
RAW 264.7NWnLVGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFKzdngyODBibl2=MnK5OFghcA>?MUjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?
A375NWLSbXNXSXCxcITvd4l{KEG|c3H5NXHh[nJqOTBibl2=NX;qPGlyOjRiaB?=NUDYSYJjUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=
BLMMU\BdI9xfG:|aYOgRZN{[Xl?M3TXXVExKG6PMnnHNlQhcA>?MYnJcoR2[2W|IHPlcIwh[XCxcITvd4l{
A375M1nRfWF2fG:yaHHnfUBCe3OjeR?=MlTKNVAhdk1?M4fjUlEzKGh?NYnhXGQ6UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>
BLMM3ryXGF2fG:yaHHnfUBCe3OjeR?=NV73SG9DOTBibl2=M3jqe|EzKGh?NV63fFNWUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>
H1299M1vxeWFxd3C2b4Ppd{BCe3OjeR?=NYnQ[lFbQDBibl2=MViyOEBpNEnnPWVFVVORNF3rW4ZU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?=
Hut-78NEPrc3NHfW6ldHnvckBCe3OjeR?=NUC5cIp[OTByIH7NNXi0cHRHOjRiaB?=MUXEUXNQM1\QNGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=
H9NHqzUWFHfW6ldHnvckBCe3OjeR?=MlHMNVAxKG6PMUCyOEBpMVrEUXNQNF[wTpZFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36=
HHMXPGeY5kfGmxbjDBd5NigQ>?M3TYWFExOCCwTR?=NIDWS|YzPCCqM3\JRWROW09?NVuyNWtN\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u
Hut-78MWDNbYdz[XSrb36gRZN{[Xl?M1\2fFExOCCwTR?=NXvMbJJuOjRiaB?=MVjEUXNQMWXS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn
HHMo\qUYloemG2aX;uJGF{e2G7M13zb|ExOCCwTR?=NIPlVW0zPCCqM4LM[mROW09?MWXS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn
U937M13jRWZ2dmO2aX;uJGF{e2G7NF\Eb20yODBibl2=MkPROkBpNHrxVYVKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W|
human PBMCMY\GeY5kfGmxbjDBd5NigQ>?Mlz3NVAxKG6PNIT5dpczPCCqNFPqbJFKdmS3Y3XzJGlNNThicnXs[YF{\Q>?
ES6M4DtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjEXphQUUN3ME2wMlAxOjFibl2=
SK-UT-1NXTGenkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYKyUVV4UUN3ME2wMlE3OyCwTR?=
SH-4MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwMUezJI5O
TE-9MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwMUiyJI5O
A253M3rIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HBZWlEPTB;MD6yNFghdk1?
no-10M3fGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDNflVKSzVyPUCuNlEhdk1?
MMAC-SFMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjrfYtKSzVyPUCuNlE3KG6P
A101DMlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj2TWM2OD1yLkKyOUBvVQ>?
NTERA-S-cl-D1M2\UeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1mzXGlEPTB;MD6yOFMhdk1?
8-MG-BANFK5PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\rXW8xUUN3ME2wMlI2KG6P
KNS-42NHH5fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT6TWM2OD1yLkK1PEBvVQ>?
LXF-289NWrKUotOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LzcmlEPTB;MD6yOlkhdk1?
OVCAR-4M2HIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37FNmlEPTB;MD6yPFkhdk1?
LOUCYNVTKU3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTBwMkmzJI5O
BB65-RCCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLPT|hmUUN3ME2wMlMxPCCwTR?=
D-542MGMlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwM{K5JI5O
ONS-76MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwM{Ogcm0>
BB30-HNCMl3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fHSGlEPTB;MD6zN|Uhdk1?
KS-1MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nUNmlEPTB;MD6zOEBvVQ>?
A388NIjaNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwM{W2JI5O
ES8MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTBwNDDuUS=>
MZ2-MELNV;xTmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fmemlEPTB;MD60NFchdk1?
HCC2998MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlm0TWM2OD1yLkSxNkBvVQ>?
D-247MGNEPoWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITKc4FKSzVyPUCuOFE{KG6P
ACNNGLQdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2f3cGlEPTB;MD60NVchdk1?
LB2518-MELNHnZR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfn[phKSzVyPUCuOFI2KG6P
ES1M4XsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3mTWM2OD1yLkSzJI5O
HCE-TM4XP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwNEO5JI5O
OS-RC-2NFfwWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTBwNESgcm0>
MFH-inoMmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjlTmhKSzVyPUCuOFQ{KG6P
OCUB-MM{nGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwNES3JI5O
CP66-MELM2H0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LSTWlEPTB;MD60O|Mhdk1?
LB771-HNCMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnhTWM2OD1yLkS3OEBvVQ>?
DSH1M1XlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLGbphKSzVyPUCuOFghdk1?
HUTU-80NYXSdW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;zeI5KSzVyPUCuOVM{KG6P
CESSNF\NZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4WwdmlEPTB;MD61N|ghdk1?
NCI-H747NFvwcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljYTWM2OD1yLkWzPUBvVQ>?
HT-144Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjBfo1oUUN3ME2wMlU4PiCwTR?=
COLO-829MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Hyb2lEPTB;MD62NVQhdk1?
A4-FukMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoKyTWM2OD1yLk[yN{BvVQ>?
GI-ME-NMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVWy[5l4UUN3ME2wMlY{PCCwTR?=
LB831-BLCMlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HvSWlEPTB;MD62OFEhdk1?
HOP-62MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\EbXVKSzVyPUCuOlQ4KG6P
BB49-HNCMoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnznTWM2OD1yLk[1NkBvVQ>?
D-336MGNX;LZm54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkW4TWM2OD1yLk[1O{BvVQ>?
TK10NWnuZZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;uTWM2OD1yLk[3PUBvVQ>?
Ramos-2G6-4C10NFiyO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwNkmzJI5O
LB373-MEL-DMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnafGEzUUN3ME2wMlchdk1?
SF126MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\5eWlEPTB;MD63NFEhdk1?
UACC-257MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPjRlBKSzVyPUCuO|Ehdk1?
KINGS-1NGPZXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHTeHl5UUN3ME2wMlczOiCwTR?=
LS-513Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTBwN{O5JI5O
GI-1NITyTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzxTWM2OD1yLke2OEBvVQ>?
ES7NVHkTYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjnblJPUUN3ME2wMlc3PiCwTR?=
LB2241-RCCNVvhXFN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\5SJg4UUN3ME2wMlgxPCCwTR?=
D-263MGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXMTWM2OD1yLkiwO{BvVQ>?
SW684M3PIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfpTWM2OD1yLkiyNUBvVQ>?
ML-2M{fNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fWRmlEPTB;MD64NlEhdk1?
SK-LMS-1MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDOfXlKSzVyPUCuPFU1KG6P
TE-5NG\z[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwOE[1JI5O
QIMR-WILNYO4bGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfOTWM2OD1yLki4PUBvVQ>?
NCI-H1355NHW4WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfMdWtjUUN3ME2wMlg6PSCwTR?=
SNB75M2jiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXs[4JKSzVyPUCuPVEzKG6P
RXF393MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfxfnFKUUN3ME2wMlkyPCCwTR?=
IST-MEL1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrhTG1HUUN3ME2wMlkyPyCwTR?=
SF268NGe1OnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXjelNYUUN3ME2wMlkzOyCwTR?=
KALS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTBwOUK1JI5O
HC-1M2m3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TaO2lEPTB;MD65O|Uhdk1?
SW872MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{S3PGlEPTB;MD65PVYhdk1?
PSN1M2XsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;lTWM2OD1zLkCxJI5O
TE-1NG[5[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DtS2lEPTB;MT6wN{BvVQ>?
TE-10NIjSeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnj5TWM2OD1zLkCzJI5O
RKONGXsOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvVbnNKSzVyPUGuNFYhdk1?
LC-2-adM3HtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\uUJBlUUN3ME2xMlA5KG6P
SK-MM-2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTFwMEmgcm0>
VA-ES-BJM2XNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDWdHcxUUN3ME2xMlA6KG6P
MZ7-melNFfYbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PNOWlEPTB;MT6wPUBvVQ>?
D-392MGM4e3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PkZWlEPTB;MT6xJI5O
CCRF-CEMM3ezd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvyZnN2UUN3ME2xMlE{KG6P
EM-2NYHHdnVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTFwMU[gcm0>
HAL-01NILxXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3OzRWlEPTB;MT6xPEBvVQ>?
TE-8NVv4fVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjZTWM2OD1zLkG5JI5O
NCI-H1882NIjzT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3qzTGlEPTB;MT6yJI5O
DaudiNHnSRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmiwTWM2OD1zLkKyJI5O
BL-41Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mof5TWM2OD1zLkK1JI5O
SRNHTSO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTFwMkWgcm0>
KM12MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDrTWM2OD1zLkK3JI5O
K5MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPGTWM2OD1zLkK4JI5O
A3-KAWNITsbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHSTWM2OD1zLkK4JI5O
CMKNYjsfJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P4fWlEPTB;MT6yPUBvVQ>?
Calu-6M1TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEe5XGhKSzVyPUGuNlkhdk1?
IST-SL2M1e0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jXO2lEPTB;MT6zNUBvVQ>?
OPM-2M33sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnu0TWM2OD1zLkOzJI5O
DU-4475MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\JTWM2OD1zLkO2JI5O
ECC12Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHW3dXdKSzVyPUGuN|chdk1?
L-540NFvLSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLWdXVFUUN3ME2xMlM4KG6P
CAS-1NYrmSpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInFblNKSzVyPUGuN|chdk1?
PF-382M{\wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\LTYhKSzVyPUGuOFchdk1?
LS-411NMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3ryTWlEPTB;MT61N{BvVQ>?
NCI-H69NEfPU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;HcmlEPTB;MT61OEBvVQ>?
NB12MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmCzTWM2OD1zLkW2JI5O
HELNGLMOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTFwNkGgcm0>
GCIYNH;KclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYryVJBEUUN3ME2xMlYzKG6P
EHEBMnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwNkegcm0>
TGBC1TKBNFPwZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3Xe3BKSzVyPUGuO|Ehdk1?
KURAMOCHINFfWeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{C1bWlEPTB;MT63NkBvVQ>?
U-266NInqfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3T1UGlEPTB;MT63OkBvVQ>?
LC4-1NGXOS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfxUHRiUUN3ME2xMlc6KG6P
NCI-H2126MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTFwODDuUS=>
NCI-H1092MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXXeIFKSzVyPUGuPEBvVQ>?
GB-1M4DZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLoZ5RKSzVyPUGuPFEhdk1?
MV-4-11M2HPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzSbHEyUUN3ME2xMlgzKG6P
BeckerNWHoblc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHLTWM2OD1zLkizJI5O
MPP-89M4fjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTFwOEmgcm0>
BE-13NGrq[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInnSldKSzVyPUGuPVMhdk1?
697M2HPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvpTWM2OD1zLkm5JI5O
NKM-1M1i0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTJibl2=
NB13NHHtNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLRTWM2OD1{IH7N
LS-123NViyeph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4j6c2lEPTB;Mj6wNkBvVQ>?
NB17M3TJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvmXnBKSzVyPUKuNFQhdk1?
LAN-6NWfVZ3NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XTdWlEPTB;Mj6wOUBvVQ>?
EW-24NHfyOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJwMEigcm0>
NOS-1NWXwc3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLJWGNKSzVyPUKuNVEhdk1?
BL-70M3zzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlj0TWM2OD1{LkGyJI5O
GT3TKBM4fyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGC2PYVKSzVyPUKuNVIhdk1?
HHNWLtVm1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXixTIJ2UUN3ME2yMlE{KG6P
KE-37M3\Kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7ldFNKSzVyPUKuNVMhdk1?
MOLT-4NVTTc21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGniWWhKSzVyPUKuNVMhdk1?
EKVXMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJwMUSgcm0>
KGNMkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfpTWM2OD1{LkG1JI5O
ES4NIHDPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwMU[gcm0>
SJSA-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFq2e3JKSzVyPUKuNlEhdk1?
KMOE-2M2m0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\BTmlEPTB;Mj6yN{BvVQ>?
NB5NInEOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7WTWM2OD1{LkK3JI5O
BC-1M1zIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfXRYJKSzVyPUKuN|Ehdk1?
NB10MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzTfJdKSzVyPUKuN|Ihdk1?
RPMI-8226NYe4WmltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvtTWM2OD1{LkO1JI5O
SCC-3NWDRRo1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnTTWM2OD1{LkO3JI5O
ARH-77MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknFTWM2OD1{LkO4JI5O
NCI-H748MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjRTWM2OD1{LkO5JI5O
KU812MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELQcHdKSzVyPUKuOFIhdk1?
NCI-H64MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTJwNESgcm0>
NB69NYKy[WRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PQbGlEPTB;Mj60OkBvVQ>?
KNS-81-FDMoj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\DTWM2OD1{LkS4JI5O
LB1047-RCCNX3GUXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{L5XGlEPTB;Mj61O{BvVQ>?
EB-3NGrOWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jpbGlEPTB;Mj62OkBvVQ>?
Mo-TNIHiZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rWfmlEPTB;Mj63OEBvVQ>?
EW-16Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Tub2lEPTB;Mj63OUBvVQ>?
CTV-1MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTJwODDuUS=>
ETK-1NXWzS4I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIqwbGhKSzVyPUKuPFQhdk1?
C2BBe1M{DuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJwOEmgcm0>
MOLT-16NUnySZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{SxNWlEPTB;Mj64PUBvVQ>?
SW954MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfuTWM2OD1{Lkmgcm0>
HTM331Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zCZ2lEPTB;Mz6wNkBvVQ>?
KARPAS-299MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTNwME[gcm0>
MONO-MAC-6MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjUTWM2OD1|LkGgcm0>
CGTH-W-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTNwMTDuUS=>
SK-PN-DWMkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{POOmlEPTB;Mz6xOEBvVQ>?
CW-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nMUWlEPTB;Mz6yNUBvVQ>?
SK-N-DZM2jHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmezTWM2OD1|LkK2JI5O
NEC8NWflfXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\pTWM2OD1|LkO1JI5O
LB996-RCCNU\RVIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTNwNDDuUS=>
DBMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXIellKSzVyPUOuOFEhdk1?
TE-15MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPxbIUzUUN3ME2zMlQ{KG6P
COR-L88NYLCT4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\6TWM2OD1|LkS3JI5O
LAMA-84MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmW1TWM2OD1|LkS5JI5O
MEG-01MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj1PFlVUUN3ME2zMlQ6KG6P
LOXIMVINH3YbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zad2lEPTB;Mz61JI5O
RPMI-8402MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrmTWM2OD1|LkWgcm0>
KARPAS-45MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\o[oRKSzVyPUOuOVQhdk1?
HCC1187NHXKRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XsNWlEPTB;Mz61OEBvVQ>?
MZ1-PCNYDBV2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULG[Zd3UUN3ME2zMlU1KG6P
no-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTNwNUWgcm0>
EVSA-TMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXsTWM2OD1|Lk[gcm0>
DJM-1NHrzWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFOyZoZKSzVyPUOuOlMhdk1?
COLO-684MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjoSlBNUUN3ME2zMlY3KG6P
NMC-G1M3TuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfGTWM2OD1|Lk[4JI5O
LC-1FNFTYT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTNwN{Sgcm0>
RL95-2M3nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTNwN{mgcm0>
COLO-320-HSRMnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PnPWlEPTB;Mz65NkBvVQ>?
RCC10RGBM1fwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF25OWZKSzVyPUOuPVMhdk1?
HD-MY-ZMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTNwOUOgcm0>
NCI-H2141MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TZRWlEPTB;ND6wOUBvVQ>?
K-562NF21c45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLQV|RZUUN3ME20MlEzKG6P
NCI-H1648NVX2W5hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PUO2lEPTB;ND6xN{BvVQ>?
OMC-1MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHGR5F3UUN3ME20MlE5KG6P
LB647-SCLCM1\0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvUTWM2OD12LkKyJI5O
TE-12M3PwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonHTWM2OD12LkK1JI5O
NOMO-1NGC1ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLid|NSUUN3ME20MlM{KG6P
RajiNVvIfWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HveWlEPTB;ND60OkBvVQ>?
NALM-6MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTJTWM2OD12LkS5JI5O
HL-60MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjQTWM2OD12Lk[3JI5O
IST-SL1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;w[o9KSzVyPUSuOlghdk1?
MHH-PREB-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTETWM2OD12Lki2JI5O
MHH-NB-11M2LIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrsUpRKSzVyPUSuPVEhdk1?
JiyoyeP-2003MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PJ[2lEPTB;NTDuUS=>
SBC-1M1:4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HRbWlEPTB;NT6wNUBvVQ>?
CHP-126MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PKTWlEPTB;NT6wOkBvVQ>?
LU-139MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULMUoJvUUN3ME21MlE{KG6P
NCI-SNU-5NVTnc5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfFToxHUUN3ME21MlE4KG6P
SW962MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDITWM2OD13LkKxJI5O
EW-1NEPlS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7qdWhKSzVyPUWuN|Ehdk1?
NCI-H1417MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\NXmlEPTB;NT61NUBvVQ>?
LU-65M1LYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTVwOESgcm0>
D-502MGNF3pZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PH[GlEPTB;Nj6zO{BvVQ>?
BC-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTZwNkGgcm0>
GDM-1NIHMcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;r[GlEPTB;Nj63O{BvVQ>?
NCI-H2196NU\2[5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fH[mlEPTB;Nj64JI5O
NB1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUi2[4pKUUN3ME22Mlg5KG6P
NCI-H345MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFW5eJJKSzVyPUeuNkBvVQ>?
SU-DHL-1M2Xn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fwS2lEPTB;Nz6yOEBvVQ>?
JVM-2M{nvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPMTWM2OD15LkK4JI5O
LU-134-AMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTdwM{mgcm0>
NCI-H1694NY\0fVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHZepBFUUN3ME23MlU5KG6P
NCI-SNU-16MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M160SmlEPTB;Nz62OUBvVQ>?
L-363Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjJTHpKSzVyPUeuO{BvVQ>?
KG-1NXLXd2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInPZ45KSzVyPUeuPVQhdk1?
MN-60NHjNTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HhNGlEPTB;OD6xOEBvVQ>?
NB6M1L5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjBTWM2OD16LkS4JI5O
MLMANHTCW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3PWnRKSzVyPUiuPFUhdk1?
ATN-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwOEmgcm0>
SK-NEP-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[0ZnJKSzVyPUmuNFEhdk1?
DMS-114NH3RU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\3V2lEPTB;OT62NkBvVQ>?
CTB-1MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrwSlhKSzVyPUmuOlchdk1?
NCI-H2081NF\ENJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnqyTWM2OD1zMD6wPUBvVQ>?
ES5MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M32w[mlEPTB;MUCuN|ghdk1?
HCC1599NUWxfYltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFzLkmxJI5O
NCI-H23NVG0N5piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGO5cYFKSzVyPUGyMlEzKG6P
NCI-H1581NG\OT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fFW2lEPTB;MUKuNlghdk1?
JVM-3M33rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfyOW9KSzVyPUGyMlk6KG6P
NCI-SNU-1MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;PSo9KSzVyPUGzMlE6KG6P
NB7NVPBZWJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTF3LkmyJI5O
JARMoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1L4PGlEPTB;MU[uNVMhdk1?
TGWMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PzOGlEPTB;MU[uOFghdk1?
U-87-MGMl7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\YRmlEPTB;MU[uO|Yhdk1?
NCI-H1436MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\SfHY2UUN3ME2xO{4xOSCwTR?=
GOTONFezSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vwWGlEPTB;MUeuNFYhdk1?
COLO-800MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTUNWEzUUN3ME2xO{43PCCwTR?=
MFM-223M4jHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:yNHhrUUN3ME2xO{46OSCwTR?=
EW-18Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DmUmlEPTB;MUeuPVYhdk1?
NB14NX3Ye5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnO0TWM2OD1zNz65PEBvVQ>?
EB2MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnuR2ZKSzVyPUG4MlA5KG6P
EoL-1-NHvMVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnOTWM2OD1zOD6zNUBvVQ>?
NCCITNX3YVmk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;KVHRKSzVyPUG4MlM3KG6P
DG-75NH3NR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLEWZRKSzVyPUG4MlYyKG6P
HCC2218NX7BVGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTF7LkWgcm0>
TE-6MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTqWoJTUUN3ME2yNE4xQCCwTR?=
SF539M4PTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorwTWM2OD1{MD62O{BvVQ>?
NCI-H446Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf2b2RKSzVyPUKxMlE5KG6P
IST-MES1M{XCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fhW2lEPTB;MkKuO|chdk1?
NCI-H82M3G5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonqTWM2OD1{Mz6wNkBvVQ>?
HCC2157M1;nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;3TWM2OD1{Mz6xN{BvVQ>?
EW-12M2i4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTJ|LkG3JI5O
SIMANFy4WY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJ|LkO4JI5O
DOHH-2M3XlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PMb2lEPTB;MkOuOFUhdk1?
IM-9MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3n3c2lEPTB;MkOuOVQhdk1?
EC-GI-10M4La[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPkXodrUUN3ME2yOE4zOyCwTR?=
HDLM-2MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HCeWlEPTB;MkSuOVQhdk1?
LS-1034NXH6WVhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX1OmtKSzVyPUK1Mlc2KG6P
REHMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHGxT|ZKSzVyPUK2MlQyKG6P
LU-165NEXF[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\ldIJLUUN3ME2yOk44OiCwTR?=
NH-12NV3CepFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTxcWU4UUN3ME2yO{43PyCwTR?=
WSU-NHLMnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTJ6LkO5JI5O
ECC4NWDZe4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\Qe|E6UUN3ME2yPE44QSCwTR?=
OCI-AML2MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nQNGlEPTB;MkmuOlkhdk1?
EW-3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TsZ2lEPTB;M{CuOVkhdk1?
NCI-H526M3y1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NESyV3lKSzVyPUOyMlU1KG6P
NCI-H719M2\SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{D3dWlEPTB;M{SuN|Ehdk1?
KARPAS-422M{TYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfLVlJKSzVyPUO1MlA1KG6P
SK-MEL-1M4nTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS1TWM2OD1|NT6xO{BvVQ>?
ES3NXS4ZXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTN3LkG5JI5O
UACC-812M4jEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTLdYI1UUN3ME2zOU41PCCwTR?=
C8166Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LmT2lEPTB;M{WuO{BvVQ>?
MDA-MB-134-VIM{frSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HGVGlEPTB;M{WuPFchdk1?
D-283MEDMoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTiN5JxUUN3ME2zO{44QSCwTR?=
SHP-77MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXwTWM2OD1|OD6wN{BvVQ>?
NCI-H2227M4ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jpO2lEPTB;NECuOFkhdk1?
SKM-1NH24SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfpd4RsUUN3ME20Nk43OyCwTR?=
L-428NX64fYRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvzcYd2UUN3ME20N{45PiCwTR?=
RPMI-6666MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjhTWM2OD12NT64PUBvVQ>?
NCI-H716NFLNSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHf6TYVKSzVyPUS4MlgyKG6P
DMS-79Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTVyLkexJI5O
RS4-11NF:1TVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTVyLki4JI5O
NCI-H720NFvy[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPOTWM2OD13MT6xNUBvVQ>?
MC-CARM1y5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LEO2lEPTB;NUGuOVIhdk1?
TALL-1NUnXN4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvTeGJpUUN3ME21N{46OSCwTR?=
NCI-N87NW\nXFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoX4TWM2OD13ND6xPEBvVQ>?
P30-OHKMkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fxRmlEPTB;NUSuOlEhdk1?
LP-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTZzLkK4JI5O
YTMly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX73Z4ZxUUN3ME22NU45KG6P
MRK-nu-1M2f1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fuemlEPTB;NkGuPFIhdk1?
BT-474MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfGPZFKSzVyPU[1JI5O
NCI-H322MMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHMN2tKSzVyPU[2MlEyKG6P
NCI-H128NV\vW2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoD6TWM2OD15ND63O{BvVQ>?
KMS-12-PENX7TXm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGL6XG1KSzVyPUe2MlI1KG6P
KP-N-YSNWTFSHRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTd4Lke0JI5O
ALL-POMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m1WmlEPTB;N{euOlYhdk1?
EW-13NFzCc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHGXnFGUUN3ME23O{44PiCwTR?=
EW-11MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTd6LkWyJI5O
SK-N-FINITqR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrrTWM2OD16MD6yJI5O
CAL-148Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXXb5lrUUN3ME24NU45PCCwTR?=
RLM2frSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDlb|JKSzVyPUi2MlA6KG6P
AM-38NGPOe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1qyXWlEPTB;OEiuNFghdk1?
RH-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHnTWM2OD17OT64OUBvVQ>?
NCI-H1770MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfVOVg6UUN3ME2xNFIvPDlibl2=
SIG-M5MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFyNT6wOkBvVQ>?
GR-STNIrwdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjzVm52UUN3ME2xNVMvOzRibl2=
ST486NEntTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzvTWM2OD1zMUSuNFYhdk1?
NCI-H1650NXLtb|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL4TWM2OD1zMUWuNlkhdk1?
MHH-CALL-2MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoexTWM2OD1zMUWuO{BvVQ>?
BV-173NWf4RXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnZTWM2OD1zMkKuO|Ehdk1?
MC116MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPZTWM2OD1zNEiuPFUhdk1?
NCI-H524M{XSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jzSGlEPTB;MUW5MlEhdk1?
SCLC-21HMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTF3OT60NUBvVQ>?
NCI-H1304M3rKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXYTWM2OD1zNkmuNlEhdk1?
NCI-H510ANHLMVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF6NT6zO{BvVQ>?
NCI-H209MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGryWYZKSzVyPUG5Ok42OiCwTR?=
KM-H2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rzTGlEPTB;MUm3MlA2KG6P
NCI-H1395NIL6WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULyVI9IUUN3ME2yNVAvOTNibl2=
NCI-H1155NULBW|hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIn0XopKSzVyPUKzNE4{OiCwTR?=
COR-L279MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPOUGdKSzVyPUK1Nk4yPyCwTR?=
NCI-H1299NHPSVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\ZTWM2OD1{NkGuO|Ehdk1?
EW-22M323bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7JXoRWUUN3ME2yOlMvPzVibl2=
SK-MEL-2NEnFbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJ6MT65JI5O
KASUMI-1NIKyRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmr1TWM2OD1{OEOuNFUhdk1?
NCI-H187MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nveWlEPTB;Mki3MlA5KG6P
NCI-H2171Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlK2TWM2OD1{OEiuPVIhdk1?
LNCaP-Clone-FGCNXyxb4U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTwV3BLUUN3ME2yPVUvOjZibl2=
NCI-H1522MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTNyNz6wOUBvVQ>?
SCHNXXqR2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Hi[GlEPTB;M{KyMlIzKG6P
THP-1Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4C1fGlEPTB;M{KyMlYhdk1?
SNU-C1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUP5Z4VoUUN3ME2zOlIvODlibl2=
CA46M2jUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTN5Mz62N{BvVQ>?
NCI-H1963NYH2fYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTN6Nj6xPUBvVQ>?
DELMnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rGR2lEPTB;M{mxMlI4KG6P
TURMlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTN7Nj62NUBvVQ>?
NCI-H226MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPVRmNKSzVyPUSwN{4zOyCwTR?=
COLO-668M{jvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LyRWlEPTB;NECzMlU4KG6P
CPC-NNW\pSXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTRyMz63O{BvVQ>?
NCI-H889NHnHc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTR4MT65NkBvVQ>?
J-RT3-T3-5NYP5[npXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml63TWM2OD13M{KuOVchdk1?
MSTO-211HMnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXaTWM2OD13N{SuNlYhdk1?
SCC-15NVrrPJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTZ4Nz60O{BvVQ>?
SUP-T1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;EOIxKSzVyPU[4Ok4xPCCwTR?=
DMS-153MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfPXGZOUUN3ME23OFYvQDNibl2=
MS-1Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVewOZZ{UUN3ME23OVkvPDJibl2=
TC-YIKNHfn[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\DTWM2OD15OEGuNFEhdk1?
RPMI-8866M1fifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzhNmQxUUN3ME2xNFA3NjJ6IN88US=>
KY821NWexZol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX32VlY6UUN3ME2xNFM3NjB2IN88US=>
P31-FUJNY\sNGpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnWyTWM2OD1zMUGyMlc2KM7:TR?=
COLO-824M1PIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\Wd2lEPTB;MUK2NU44QCEQvF2=
U-698-MM4DZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljVTWM2OD1{Mk[yMlE2KM7:TR?=
TE-441-TNYj4W2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofxTWM2OD1{NUKxMlch|ryP
IMR-5NHHNXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rFUWlEPTB;M{SwPU43OiEQvF2=
NCI-H1838NEnt[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXNRZNKSzVyPUSxPFYvOzJizszN

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-06-27)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02343042 Not yet recruiting Multiple Myeloma Karyopharm Therapeutics, Inc September 2015 Phase 1|Phase 2
NCT02440464 Not yet recruiting Multiple Myeloma National Heart, Lung, and Blood Institute (NHLBI)|Blood a  ...more National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) July 2015 Phase 2
NCT02441686 Not yet recruiting Multiple Myeloma Dana-Farber Cancer Institute|Millennium Pharmaceuticals,  ...more Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene Corporation June 2015 Phase 2
NCT02375555 Recruiting Multiple Myeloma Dana-Farber Cancer Institute|Bristol-Myers Squibb May 2015 Phase 2
NCT02356458 Not yet recruiting Mantle Cell Lymphoma Swiss Group for Clinical Cancer Research May 2015 Phase 1|Phase 2

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Customer Product Validation (19)


Click to enlarge
Rating
Source Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck
Method Western blots
Cell Lines Primary myoblasts
Concentrations 10, 50 uM
Incubation Time 24 h
Results To demonstrate the biological functionality of the salvaged missense mutated dysferlin protein, we performed membrane resealing experiments on primary myoblasts derived from percutaneous muscle biopsies taken from patient 2. Bortezomib treatment of primary myoblasts increased dysferlin expression in a dose-dependent manner, and bortezomib-treated myoblasts regained their capability to reseal laser-induced plasma membrane injuries.

Click to enlarge
Rating
Source J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck
Method Fluorescence
Cell Lines Primary myoblasts
Concentrations 2 mg/kg
Incubation Time 2 weeks
Results To examine this further, it determined whether inhibition of the proteasome with bortezomib blocked proplatelet formation in murine megakaryocytes. Similar responses were observed in human megakaryocytes, and removal of bortezomib from the incubation media restored proplatelet formation.

Click to enlarge
Rating
Source J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines Mouse primary osteoblasts
Concentrations 25 nM
Incubation Time 2 h
Results In support of this idea, the PTH-induced decrease of HDAC4 accumulation in osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib.

Click to enlarge
Rating
Source Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck
Method H&E staining, Western blots, TUNEL assays
Cell Lines Foxp3flox/yxPBCre4+ mice
Concentrations 1 mg/kg
Incubation Time 60 weeks
Results Reduced cell proliferation was also observed in prostate epithelial cells of bortezomib-treated mice by Ki67 staining analysis (A). Furthermore, lack of nuclear p65 was observed in the bortezomib-treated prostate at 12 hours after LPS injection (B). To verify the impact of bortezomib treatment on NF-kB activation, we observed the expression of NF-kB targets in the mouse prostate. In contrast to the prostate-specific expression in untreated Foxp3cKO mice, the expression levels of Bcl2l1 and Traf1/2 were significantly downregulated in the prostates of treated mice (C). Importantly, the percentage of apoptotic prostate epithelial cells increased after bortezomib treatment (D).

Click to enlarge
Rating
Source Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence microscopy
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 45 min
Results Bortezomib and NH4Cl also increased the adjacency of DRIPs to SGs.

Click to enlarge
Rating
Source Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines wild-type oocytes, Fmn2-/-oocytes
Concentrations 0.1 μM
Incubation Time 90 min
Results Endogenous Fmn2, localized in the cortex of prophase I oocytes, disappeared at NEBD, reappeared later and was enriched in the cortex opposite the spindle. Fmn2 -/-oocytes lacked cortical Fmn2 staining, suggesting that the staining is specific. Cortical localization was maintained at NEBD in wild-type oocytes treated with the proteasome inhibitor, Bortezomib, indicating that Fmn2 is degraded at NEBD.

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Bortezomib and other inhibitors tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Bortezomib, Lapatinib, and LY294002 significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells.

Click to enlarge
Rating
Source J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck
Method Real Time PCR
Cell Lines HepAD38 cells
Concentrations 2-50 nM
Incubation Time 18 h
Results An inhibitory effect of proteasome inhibition by bortezomib on HBV replication can be observed in cell culture.Therefore, proteasome activation seems to be a valuable strategy of the infected cells to reduce the stress resulting from misfolded proteins.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 0.1-10 μM
Incubation Time 1/7 h
Results Proteasome inhibitors which have different inhibition mechanisms, such as bortezomib and lactacystin, had a strong effect on virus replication in parallel with an increase in p53 accumulation.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 10 μM
Incubation Time 5-10 h
Results Further kinetic experiments were performed to better define the time window within the viral replication cycle in which proteasome activity was required. For this, cells were infected for 1 h and treated with MG132 or bortezomib for 4h at different times postinfection (Fig. A). As shown in Fig. B, a more clear arrest on viral protein accumulation was observed when bortezomib or MG132 was added at relatively earlier time points. Indeed, when inhibitors were added at 5 h p.i. or later, the effect was much reduced, suggesting that once the infection was well established with a robust accumulation of viroplasms, the requirement for proteasome activity was less significant.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines NSP5-EGFP cells
Concentrations 10 μM
Incubation Time 2-8 h
Results Both MG132 and bortezomib induced a significant arrest on the formation of viroplasms, which appeared in reduced number and with smaller size with respect to those in control cells, particularly when added at time points between 1 h and 5 h p.i.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Quantification of viroplasms
Cell Lines NSP5-EGFP cells, MA104 cells
Concentrations 10 μM
Incubation Time 4 h
Results The number of viroplasms per cell in cells treated for 4 h with MG132 or bortezomib was almost the same as that found in cells fixed at the beginning of each treatment, strongly suggesting that inhibition of proteasome activity affected the assembly of new viroplasms and their growth.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Proteasome activity assay, Standard plaque assay
Cell Lines A549 cells
Concentrations 10-100 nM
Incubation Time 1 h
Results As expected bortezomib treatment resulted in a block of viral replication of the avian influenzavirus strain A/FPV/Bratislava/79 (H7N7; FPV) in a concentration-dependent manner. While concentrations of 10 nM had no antiviral effect, 50 nM led to a significant titer reduction of up to 3 orders of magnitude (Fig.A). The highest concentration used (100 nM) led to a titer reduction of up to 4 orders of magnitude.These results were also confirmed in a virus growth kinetics study in infected cells that received a single dose of 50nM bortezomib. Virus titers were reduced at every time point analyzed (Fig.C).Since bortezomib is a proteasome inhibitor, we investigated whether the antiviral concentrations of bortezomib may have an inhibitory effect on the 26S proteasome in A549 cells. A concentration-dependent inhibition of the proteasome was observed in FPV-infected A549 cells at 24 h p.i. (Fig. B).

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Standard plaque assay, Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1-10 h
Results A strong antiviral activity of bortezomib was observed upon addition of the compound up to 2 h p.i. At time points of 4 h p.i. and later, a dramatic decrease in the antiviral efficacy was observed. This indicates that the event in the viral life cycle that is affected by bortezomib occurs within the first 4 h. Since this correlates with the strong onset of viral gene and protein expression, we analyzed whether viral protein accumu-lation is affected by bortezomib. Indeed, we observed a strong reduction in viral matrix protein (M1) and PB1 polymerase synthesis in FPV- and PR8-infected cells at 5 h and 8 h p.i.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1/6/24 h
Results After a 6-h treatment with 50 nM bortezomib, activation of JNK was detected as evidenced by phosphorylation of the kinase at Thr183 and Tyr185 (lane 4). This was even enhanced upon a 24-h treatment (lane 6). Downstream substrates of JNK are the AP-1 transcription factors c-Jun and ATF-2, which are activated by JNK-mediated phosphorylation at Ser63 and Thr71, respectively. Consistent with JNK activation, we also found c-Jun and ATF-2 were phosphorylated and activated( lane 6), leading to the conclusion that, besides NF-κB, the JNK/c-Jun/ATF-2 pathway is also activated in A549 upon bortezomib treatment.

Click to enlarge
Rating
Source PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 50 μM
Incubation Time 4 h
Results Upon proteasome inhibition by Bortezomib an increased amount of around 5-6 fold of biotinylated molecules was detected, both in the absence and presence of US2 and US11.

Click to enlarge
Rating
Source 2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck
Method Western Blotting
Cell Lines KKU-M213 cells
Concentrations 0/20/40 nM
Incubation Time 0-12 h
Results We checked the effects of BTZ on the NF-κB pathway in KKU-M213 (Fig. a, b). BTZ induced IκB phosphorylation in dose- and time-dependent manners (Fig. a). Interestingly, reduced IκB was observed over time until it was barely detectable 12 h after treatment; as a result, nuclear NF-κB (p65) was markedly increased (Fig. b).

Click to enlarge
Rating
Source Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck
Method PB assay
Cell Lines S2-013
Concentrations
Incubation Time 24 h
Results It is noticed more deleterious effects by free bortezomib than by BTZ CS/GA nanoparticles.

Product Use Citation (141)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • PI-1840

    PI-1840 is a reversible and selective chymotrypsin-like (CT-L) inhibitor with IC50 of 27 nM with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L).

  • SB-3CT

    SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

  • Leupeptin Hemisulfate

    Leupeptin Hemisulfate is a reversible inhibitor of serine and cysteine proteases.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us